CSL Wins Australian Approval for Avian Flu Vaccine
Posted on: Tuesday, 17 June 2008, 09:01 CDT
CSL has received approval from the Australian Therapeutic Goods Administration to register Panvax, the company's avian influenza vaccine.
Developed by CSL in collaboration with the Australian government, Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus.
CSL is said to be the only vaccine supplier that manufactures influenza vaccines in Australia. Through its recent and continuing investment of more than $80m in Fluvax (a vaccine against seasonal influenza) CSL remains committed to the ongoing provision of influenza vaccines to the Australian community.
Mary Sontrop, general manager of CSL Biotherapies, a group member company of CSL and the business unit responsible for developing and manufacturing Panvax, said: "In the event of a pandemic, CSL will rapidly gear up to manufacturing levels that will ensure all Australians have access to safe, effective coverage against avian flu. We continue to work collaboratively with the World Health Organization and with the Australian scientific community to maintain a high level of avian flu preparedness."
Source: Datamonitor
Related Articles
- Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
- Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
- Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria(R) Published in Vaccine
- Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
- National Foundation for Infectious Diseases Receives Grant From CSL Biotherapies to Increase Flu Vaccination Rates Among Healthcare Workers
- Single Injection of Vical's Avian Flu DNA Vaccine Provides 100% Protection in Ferrets
- Live H5N1 Avian Flu Virus Vaccines Show Protection in Animal Studies
- Recombinomics Presents Data and Analysis on Pandemic and Seasonal Influenza Evolution at Novel Vaccines Conference in Cambridge, Massachusetts
- Triangle Science Collaboration Could Impact Influenza, Avian Flu Treatment
- Australian Flu-Vaccine Firm Talks With FDA
 |
 |
User Comments (0)
RSS Feeds